Key catalysts approach for Orphazyme, Gemini and Immutep.
Better-looking safety might not be enough to get Solid back in the Duchenne muscular dystrophy game.
Amicus follows Sanofi with disappointing pivotal Pompe data, casting further doubt on approvals.
And the move will shake up the orthopaedic robotics scene.
Sarepta’s first ever controlled study, of a Duchenne muscular dystrophy gene therapy, brings the markets down to earth.